[Edaily Reporter Park Jung-Soo ] Global health and lifestyle company H.PIO Co.,Ltd(357230), having posted its highest-ever first-half sales, is now stepping up shareholder returns through a share buyback and cancellation. H.PIO Co.,Ltd announced on the 24th that it held a board of directors meeting and decided to retire all 191,003 shares of treasury stock it currently holds. The retirement, valued at approximately 550 million won, is scheduled for September 11. The treasury stock to be retired consists of shares H.PIO Co.,Ltd acquired between March and May of this year with the aim of enhancing shareholder value. H.PIO Co.,Ltd is expanding its shareholder return policy based on its earnings growth. In September of last year, the company retired 796,011 treasury shares worth approximately 9 billion won, and this year, it implemented a dividend policy with a dividend payout ratio of 29%. This expansion of shareholder returns is driven by earnings growth. Thanks to the revenue growth of its major subsidiaries, H.PIO Co.,Ltd recorded sales of 141.8 billion won in the first half of this year, achieving its highest-ever half-year sales. For the second half of the year, the company plans to sustain this growth momentum through the launch of new products by H.PIO Co.,Ltd and its major affiliates. H.PIO Co.,Ltd intends to increase the proportion of sales from domestically produced products to enhance cost competitiveness, while BioPharm plans to drive sales growth and improve profitability by expanding overseas exports. H.PIO Co.,Ltd. stated, “Following our record-high revenue in the first half of this year, we will maintain a robust performance trend in the second half through growth in our core business and major affiliates,” adding, “We plan to actively utilize the funds secured through business growth to secure future growth engines and enhance shareholder value.” The official added, “Moving forward, we will continue our shareholder return policy of directly sharing our performance with shareholders based on earnings growth to build trust and create a virtuous cycle where the company and shareholders grow together.”
As a chill sweeps through the European private equity market in the wake of interest rate hikes, the financial clout of major U.S.-based asset managers is coming to the fore. Although transactions hav…
The retail industry came under fire during the National Assembly’s parliamentary audit, facing criticism ranging from allegations of anti-competitive practices by food delivery apps to controversies o…
L&C BIO has signed an exclusive supply agreement worth at least $61.2 million (approximately 83.7 billion won) with a U.S.-based human tissue specialist and tissue bank for its human tissue skin extra…